FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:289-290 January 27, 2000 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Torp-Pedersen, C.

To the Editor: Contemporary pharmacotherapy for patients with advanced congestive heart failure (New York Heart Association functional class III or IV) typically involves the concomitant use of digoxin, loop diuretics, angiotensin-converting–enzyme inhibitors, and increasingly, beta-blockers. In the September 16 issue of the Journal, Torp-Pedersen and coworkers¹ reported that dofetilide had a neutral effect on the risk of death from any cause, reduced the risk of hospitalization for worsening congestive heart failure, and was effective in restoring (and maintaining) sinus rhythm in patients with atrial fibrillation. However, it is unclear whether therapy with digoxin was an exclusion criterion, according to the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Nagra, B. S., Ledley, G. S., Kantharia, B. K. (2005). Marked QT Prolongation and Torsades de Pointes Secondary to Acute Ischemia in an Elderly Man Taking Dofetilide for Atrial Fibrillation: A Cautionary Tale. J CARDIOVASC PHARMACOL THER 10: 191-195 [Abstract]